Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Infant Antibody Repertoires during the First Two Years of Influenza Vaccination. | mBio | 2022 | 36314798 | PubTator, text mining | PubMed |
| Therapeutic Management of Chronic Lymphocytic Leukemia Presenting with Recurrent Massive Ascites. | Curr Oncol | 2022 | 36290811 | PubTator, text mining | PubMed |
| The role of NPM1 alternative splicing in patients with chronic lymphocytic leukemia. | PLoS One | 2022 | 36282861 | PubTator, text mining | PubMed |
| Identifying a novel ferroptosis-related prognostic score for predicting prognosis in chronic lymphocytic leukemia. | Front Immunol | 2022 | 36275721 | PubTator, text mining | PubMed |
| In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia. | Sci Rep | 2022 | 36271116 | PubTator, text mining | PubMed |
| Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. | Nat Commun | 2022 | 36266272 | PubTator, text mining | PubMed |
| Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab. | Front Oncol | 2022 | 36249044 | PubTator, text mining | PubMed |
| Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction. | Front Immunol | 2022 | 36248816 | PubTator, text mining | PubMed |
| CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. | Cancers (Basel) | 2022 | 36230840 | PubTator, text mining | PubMed |
| Establishment and evaluation of module-based immune-associated gene signature to predict overall survival in patients of colon adenocarcinoma. | J Biomed Sci | 2022 | 36229806 | PubTator, text mining | PubMed |
| Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study. | Clin Hematol Int | 2022 | 36227519 | PubTator, text mining | PubMed |
| Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature. | Clin Case Rep | 2022 | 36225619 | PubTator, text mining | PubMed |
| Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry. | Pathol Oncol Res | 2022 | 36213161 | PubTator, text mining | PubMed |
| Immune repertoire and evolutionary trajectory analysis in the development of diabetic nephropathy. | Front Immunol | 2022 | 36211355 | PubTator, text mining | PubMed |
| Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia. | Curr Med Res Opin | 2022 | 36205521 | PubTator, text mining | PubMed |
| Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study. | PLoS One | 2022 | 36201482 | PubTator, text mining | PubMed |
| Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development. | Hum Vaccin Immunother | 2022 | 36194773 | PubTator, text mining | PubMed |
| Super-Enhancer-Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients. | Front Genet | 2022 | 36186463 | PubTator, text mining | PubMed |
| BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. | J Hematol Oncol | 2022 | 36183125 | PubTator, text mining | PubMed |
| Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation. | Mol Biol Rep | 2022 | 36169893 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=26